agilon health, inc. (AGL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 600M 1.2B 1.8B Q1 '20: 291M Q2 '20: 293.6M Q3 '20: 312.7M Q4 '20: 321M Q1 '21: 413.1M Q2 '21: 499M Q3 '21: 458.6M Q4 '21: 150.8M Q1 '22: 653.4M Q2 '22: 670.1M Q3 '22: 694.9M Q4 '22: 369.8M Q1 '23: 1.1B Q2 '23: 1.1B Q3 '23: 1.1B Q4 '23: 1.1B Q1 '24: 1.6B Q2 '24: 1.5B Q3 '24: 1.5B Q4 '24: 1.5B Q1 '25: 1.5B Q2 '25: 1.4B Q3 '25: 1.4B Q4 '25: 1.6B Q1 '26: 1.4B Q2 '26: 1.5B Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-300M -150M 0 150M 300M 450M Q1 '20: -5.8M Q2 '20: -1.3M Q3 '20: -9.8M Q4 '20: -39.7M Q1 '21: -12.1M Q2 '21: -298.4M Q3 '21: -35.6M Q4 '21: -26.2M Q1 '22: -743K Q2 '22: -21.1M Q3 '22: -29.5M Q4 '22: -54.1M Q1 '23: 417K Q2 '23: -29M Q3 '23: -39.3M Q4 '23: -164.3M Q1 '24: -7.2M Q2 '24: -43.3M Q3 '24: -133.5M Q4 '24: -108.1M Q1 '25: -22.1M Q2 '25: -116M Q3 '25: -131.3M Q4 '25: -193.8M Q1 '26: 4M Q2 '26: 11.8M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income Quarterly

-300M -150M 0 150M 300M 450M Q1 '20: -16.1M Q2 '20: -7.9M Q3 '20: -11.8M Q4 '20: -24.2M Q1 '21: -15.1M Q2 '21: -298.8M Q3 '21: -35.8M Q4 '21: -56.7M Q1 '22: 1.2M Q2 '22: -20.6M Q3 '22: -30.7M Q4 '22: -56.5M Q1 '23: 16M Q2 '23: -16.7M Q3 '23: -31.4M Q4 '23: -230.4M Q1 '24: -6.1M Q2 '24: -30.7M Q3 '24: -117.6M Q4 '24: -105.8M Q1 '25: 12.1M Q2 '25: -104.4M Q3 '25: -110.2M Q4 '25: -188.9M Q1 '26: 48.9M Q2 '26: 18M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '20: -26.1M Q2 '20: -9.4M Q3 '20: -4.4M Q4 '20: -13.3M Q1 '21: -40.8M Q2 '21: -39.3M Q3 '21: -19.1M Q4 '21: -48.9M Q1 '22: -23.2M Q2 '22: -60.3M Q3 '22: 2.6M Q4 '22: -50M Q1 '23: -60.8M Q2 '23: -21.2M Q3 '23: -13M Q4 '23: -61.2M Q1 '24: -47.8M Q2 '24: -18.7M Q3 '24: -7.7M Q4 '24: 16.4M Q1 '25: -32M Q2 '25: -35.1M Q3 '25: -18.2M Q4 '25: -20.5M Q1 '26: 23.7M Q2 '26: -57.3M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q1 '20: -26.5M Q2 '20: -10M Q3 '20: -4.7M Q4 '20: -13.9M Q1 '21: -41M Q2 '21: -39.8M Q3 '21: -21.7M Q4 '21: -52.3M Q1 '22: -27.3M Q2 '22: -64.7M Q3 '22: -786K Q4 '22: -53.4M Q1 '23: -64.5M Q2 '23: -25.3M Q3 '23: -17.1M Q4 '23: -65.1M Q1 '24: -50.9M Q2 '24: -22M Q3 '24: -11.2M Q4 '24: 13.2M Q1 '25: -35.8M Q2 '25: -38.3M Q3 '25: -21.3M Q4 '25: -23.5M Q1 '26: 20.6M Q2 '26: -60.7M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q1 '21: 325.7M Q2 '21: 377.4M Q3 '21: 391.2M Q1 '22: 424.1M Q2 '22: 407.3M Q3 '22: 411.1M Q1 '23: 426.6M Q2 '23: 410.3M Q3 '23: 405.8M Q1 '24: 408.9M Q2 '24: 411.3M Q3 '24: 411.6M Q1 '25: 16.5M Q2 '25: 16.6M Q3 '25: 414.5M Q1 '26: 16.7M Q2 '26: 17.2M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.